Ruffo Frank 4
4 · Aclaris Therapeutics, Inc. · Filed Jun 2, 2021
Insider Transaction Report
Form 4
Ruffo Frank
Chief Financial Officer
Transactions
- Sale
Common Stock
2021-06-02$22.30/sh−2,450$54,635→ 169,872 total - Exercise/Conversion
Restricted Stock Units
2021-06-01−33,189→ 0 total→ Common Stock (33,189 underlying) - Exercise/Conversion
Common Stock
2021-06-01+33,189→ 184,909 total - Sale
Common Stock
2021-06-02$21.51/sh−12,587$270,748→ 172,322 total
Footnotes (5)
- [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- [F2]Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections.
- [F3]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.06 to $22.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.06 to $22.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020.